Advertisement

Botulinumtoxin — neuer Therapieansatz bei Muskelverspannungen und myofaszialen Beschwerden

  • H. Hefter
  • A. Chalkiadaki
  • G. Gerats
  • S. Kelm
Conference paper

Zusammenfassung

Nachdem A. Scott Botulinumtoxin A (BoNT-A) zur Kompensation muskulärer Überaktivität beim Schielen erstmals klinisch erfolgreich eingesetzt hatte [35], wurde in den folgenden Jahren BoNT-A mit großem therapeutischen Erfolg zur Behandlung von fokalen Dystonien im Gesichts- und Kopfbereich eingesetzt [3], [19], [23]. Auch zur Korrektur von Gesichtsfalten wurde BoNT-A bald eingesetzt [2], [5]. Mittlerweile ist BoNT-A Mittel der ersten Wahl in der Behandlung des Blepharospasmus, der oromandibulären Dystonie und der fokalen zervikalen Dystonien [25], [26].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Barwood S, Baillieu C, Boyd R, Brereton K, Low J, Nattrass G, Graham HK (2000) Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol 42, 2116–2121CrossRefGoogle Scholar
  2. 2.
    Blitzer A, Brin MF, Keen MS, Aviv JE (1993) Botulinumtoxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 119,9:1018–1022PubMedCrossRefGoogle Scholar
  3. 3.
    Brin MF, Fahn S, Moskowitz C, Friedmann A, Shale HM, Greene PE, Blitzer A, List T, Lange D, Lorelace RE (1987) Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2,4:237–254PubMedCrossRefGoogle Scholar
  4. 4.
    Brin MF, Swope DM, O’Brian C, Abbasi S, Pogoda JM (2000) Botox for migraine: double-blind, placebo-controlled region-specific evaluation. Cephalalgia 20: 421–422CrossRefGoogle Scholar
  5. 5.
    Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18,1:17–21PubMedCrossRefGoogle Scholar
  6. 6.
    Carruthers A, Langtry JAA, Carruthers JA, Robinson G (1999) Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 39:662–665PubMedCrossRefGoogle Scholar
  7. 7.
    Cheshire WP, Abashian SW, Mann JD (1994) Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59,1:65–69PubMedCrossRefGoogle Scholar
  8. 8.
    Frueh BR, Mush DC (1986) Treatment of facial spasm with Botulinumtoxin. An interim report. Ophthalmology 93,7:917–923PubMedGoogle Scholar
  9. 9.
    Filippi GM, Errico P, Santarelli R, Bagolini B, Mann E (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400–404PubMedCrossRefGoogle Scholar
  10. 10.
    Foster L, Clapp L, Erickson M, Jabbari B (2001) Botulinum toxin A and chronic low back pain. A randomized, double-blind study. Neurology 56:1290–1293PubMedCrossRefGoogle Scholar
  11. 11.
    Freund B, Schwartz M (2000) The use of Botulinumtoxin A in the treatment of refractory cluster headache: case reports. Cephalalgia 20:329–330Google Scholar
  12. 12.
    Giladi N (1997) The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 152:132–135PubMedCrossRefGoogle Scholar
  13. 13.
    Ginies PR, Fraimont JL, Kong A Siou D, Chevallier J, Mann C, Colson P (1996) Treatment of cluster headache by subcutaneous injection of Botulinumtoxin. 8th World Congress of Pain. Poster presentation, p 50Google Scholar
  14. 14.
    Girdler NM (1994) Use of Botulinumtoxin to alleviate facial pain. Br J Hosp Med 52,7:363PubMedGoogle Scholar
  15. 15.
    Göbel H, Heinze A, Heinze-Kuhn K, Jost WH (2001) Evidence-based medicine: botulinumtoxin A in migraine and tension-type headache. J Neurol 248(Suppl 1): I/34–I/38Google Scholar
  16. 16.
    Göbel H, Heinze A, Heinze-Kuhn K, Austermann K (2001) Botulinum-Toxin A in der Therapie von Kopfschmerzerkrankungen und perikranialen Schmerzsyndromen. Nervenarzt 72:261–274PubMedCrossRefGoogle Scholar
  17. 17.
    Guyer BM (1999) Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 3:427–431PubMedCrossRefGoogle Scholar
  18. 18.
    Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K (2000) Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44, 2:106–109PubMedCrossRefGoogle Scholar
  19. 19.
    Jankovic J, Schwartz K (1990) Botulinumtoxin injections for cervical dystonia. Neurology 40:277–280PubMedCrossRefGoogle Scholar
  20. 20.
    Jensen R, Olesen R (2000) Tension-type headache: an update on mechanisms and treatment. Curr Opin Neurol 13:285–289PubMedCrossRefGoogle Scholar
  21. 21.
    Kelm S, Gerats G, Chalkiadaki A, Hefter H (2001) Reduktion von Schmerz und Muskelanspannung durch Botulinumtoxin A. Nervenarzt 72:302–306PubMedCrossRefGoogle Scholar
  22. 22.
    Krack P, Hornig C, Dorndorf W (1995) Resolution of chronic tension headache after Botulinumtoxin treatment of idiopathic blepharospasm. Mov disord 10:388Google Scholar
  23. 23.
    Mauriello JA Jr (1985) Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with Botulinumtoxin. Neurology 35:1499–1500PubMedCrossRefGoogle Scholar
  24. 24.
    Mense S, Simons DG (2001) Muscle Pain. Understanding its nature, diagnosis, and treatment. Lippincott Williams and Wilkins, Baltimore, MDGoogle Scholar
  25. 25.
    Moore P (1995) Handbook of Botulinum toxin treatment. Blackwell Science Ltd, OxfordGoogle Scholar
  26. 26.
    Naumann M, Hefter H, Heinen F (1998) Botulinumtoxin. Wirkprinzip und klinische Anwendung. UNI-MED-Verlag, BremenGoogle Scholar
  27. 27.
    Porta M (2000). A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 85:101–105PubMedCrossRefGoogle Scholar
  28. 28.
    Purkiss JR, Welch MJ, Doward S, Foster KA, Quinn CP (1998) A method for the measurement of [3H]-glutamate release from cultured dorsal root ganglion neurons. Biochem Soc Trans 26:108Google Scholar
  29. 29.
    Relja MA (1997) Treatment of tension-type headache by local injection of Botulinumtoxin. Eur J Neurol 4(suppl 2):71–73Google Scholar
  30. 30.
    Relja MA (2000) Treatment of tension-type headache with Botulinumtoxin: 1-year follow-up. Cephalalgia 20:336Google Scholar
  31. 31.
    Relja M, Korsic M (1999) Treatment of tension-type headache by injections of botulinum toxin type A: double-blind placebo controlled study. Neurology 52:A203Google Scholar
  32. 32.
    Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R (2000) Treatment of tension-type headache with Botulinumtoxin type A: A double-blind, placebo-controlled study. Headache 40,4:300–305PubMedCrossRefGoogle Scholar
  33. 33.
    Rosales RL, Arimura K, Takenaga S, Osame M (1996) Extrafusal and intrafusal muscle effects in experimental Botulinumtoxin-A injection. Muscle Nerve 19,4:488–496PubMedCrossRefGoogle Scholar
  34. 34.
    Schulte-Mattler WJ, Wieser T, Zierz S (1999) Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res 4:183–186PubMedGoogle Scholar
  35. 35.
    Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044–1049PubMedGoogle Scholar
  36. 36.
    Silberstein S, Mathew N, Saper J, Jenkins S (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40:445–450PubMedCrossRefGoogle Scholar
  37. 37.
    Simons DG, Mense S (1998) Understanding and measurement of muscle tone as related to clinical muscle pain. Pain 75:1–17PubMedCrossRefGoogle Scholar
  38. 38.
    Smuts JA, Baker MK, Smuts HM, Stassen JMR, Rossouw E, Barnard PWA (1999) Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol 6(Suppl 4):99–102CrossRefGoogle Scholar
  39. 39.
    Tarsy D (1997) Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 12:100–102PubMedCrossRefGoogle Scholar
  40. 40.
    Tarsy D, First ER (1999) Painful cervical dystonia: clinical features and response to treatment with botulinum toxin. Mov Disord 14,6:1043–1045PubMedCrossRefGoogle Scholar
  41. 41.
    Travell JG, Simons DG (1983) Myofascial Pain and Dysfunction: The Trigger Point Manual, Vol. 1, Williams and Wilkins, Baltimore, MDGoogle Scholar
  42. 42.
    Travell JG, Simons DG (1992) Myofascial Pain and Dysfunction: The Trigger Point Manual, Vol. 2, Williams and Wilkins, Baltimore, MDGoogle Scholar
  43. 43.
    Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38,2:245–258PubMedCrossRefGoogle Scholar
  44. 44.
    Wheeler AH, Goolkasian P, Gretz SS (1998) A randomized, double-blind, prospective pilot study of Botulinumtoxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 23,15:1662–1666PubMedCrossRefGoogle Scholar
  45. 45.
    Wolfe F, Smythe HA, Yunus MB et al. (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 33:160–172PubMedCrossRefGoogle Scholar
  46. 46.
    Zwart JA, Bovim G, Sand T, Sjaastad (1994) Tension headache: Botulinumtoxin paralysis of temporal muscles. Headache 34,8:458–462PubMedCrossRefGoogle Scholar
  47. 47.
    Yokosawa N, Suga K, Kimura K, Tsuzuki K, Fujii N, Oguma K, Yokosawa H (1994) Exogenous zinc ion is required for inhibitory activity of botulinum neurotoxin C1 against norepinephrine release and its endopeptidase activity toward substance P. Biochem Mol Biol Int 32,3:455–463PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • H. Hefter
  • A. Chalkiadaki
  • G. Gerats
  • S. Kelm

There are no affiliations available

Personalised recommendations